Arbutus Biopharma (ABUS) Set to Release Quarterly Earnings on Monday

Arbutus Biopharma (NASDAQ:ABUS) is anticipated to release its Q3 2026 resultson Monday, November 16th. Analysts expect Arbutus Biopharma to announce earnings of ($0.0232) per share and revenue of $1.00 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:30 AM ET.

Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Arbutus Biopharma had a return on equity of 90.98% and a net margin of 84.22%. The company had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $0.70 million.

Arbutus Biopharma Stock Performance

ABUS opened at $3.65 on Monday. The stock has a market capitalization of $723.10 million, a price-to-earnings ratio of 4.62 and a beta of 0.84. The company has a fifty day moving average of $4.58 and a 200 day moving average of $4.48. Arbutus Biopharma has a fifty-two week low of $3.50 and a fifty-two week high of $5.45.

Arbutus Biopharma announced that its Board of Directors has initiated a share repurchase plan on Friday, August 21st that authorizes the company to buy back shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded Arbutus Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Arbutus Biopharma has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing novel therapies for chronic hepatitis B virus (HBV) infection. Its research is aimed at addressing multiple stages of the HBV lifecycle, with the long-term goal of developing functional cures rather than therapies that only suppress the virus.

The company’s pipeline has included investigational medicines such as AB-729, an RNA interference therapeutic designed to reduce hepatitis B surface antigen, and other antiviral candidates intended to inhibit viral replication.